Xeris Biopharma Holdings, Inc. announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for the XP-8121 patent application.
The patent covers XP-8121, a novel product candidate designed to address hypothyroidism, demonstrating the company's commitment to developing innovative solutions.
This milestone strengthens Xeris' intellectual property protection and highlights the potential of their XeriSol® platform for subcutaneous injections.
Notice of Allowance for XP-8121 Patent
USPTO granted a Notice of Allowance for Xeris' XP-8121 patent application, a significant step towards patent issuance.
Impact on Hypothyroidism Treatment
XP-8121's unique liquid formulation offers potential benefits over traditional oral levothyroxine, addressing limitations in absorption and effectiveness.
Strengthening IP Protection
The allowed patent claims enhance Xeris' IP portfolio, securing their position in the hypothyroidism treatment market.
- The Notice of Allowance indicates USPTO's recognition of XP-8121's innovation and the company's ability to address medical needs.
- Xeris' focus on developing novel solutions for challenging conditions like hypothyroidism shows promise for improving patient outcomes and expanding their product portfolio.
Xeris Biopharma's acknowledgment from the USPTO marks a significant achievement in their quest to advance treatments for hypothyroidism. This recognition reaffirms the company's dedication to innovation and intellectual property protection.